| Literature DB >> 24900338 |
Scott T Harrison1, James Mulhearn1, Scott E Wolkenberg1, Patricia J Miller1, Stacey S O'Malley1, Zhizhen Zeng1, David L Williams1, Eric D Hostetler1, Sandra Sanabria-Bohórquez1, Linda Gammage1, Hong Fan1, Cyrille Sur1, J Christopher Culberson1, Richard J Hargreaves1, Jacquelynn J Cook1, George D Hartman1, James C Barrow1.
Abstract
5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential (18)F containing β-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human β-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of β-amyloid plaque load.Entities:
Keywords: Alzheimer’s disease; PET; fluorine-18; oxazolo[5,4-b]pyridine; positron emission tomography; β-amyloid plaque
Year: 2011 PMID: 24900338 PMCID: PMC4018077 DOI: 10.1021/ml200018n
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345